2018

Peer Reviewed Publications in Print or Other Media

 

Parp3 promotes long-range end joining in murine cells

Layer, Jacob V., Cleary, J. Patrick, Brown, Alexander J., Stevenson, Kristen E., Morrow, Sara N., Van Scoyk, Alexandria, Blasco, Rafael B., Karaca, Elif, Meng, Fei-Long, Frock, Richard L., Tivey, Trevor, Kim, Sunhee, Fuchs, Hailey, Chiarle, Roberto, Alt, Frederick W., Roberts, Steven A., Weinstock, David M., and Day, Tovah A. "Parp3 Promotes Long-range End Joining in Murine Cells." Proceedings of the National Academy of Sciences of the United States of America.True, no. True, True.

Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles

 Hellmuth, J. C., Louissaint, A., Szczepanowski, M., Haebe, S., Pastore, A., Alig, S., Staiger, A. M., Hartmann, S., Kridel, R., Ducar, M. D., Koch, P., Dreyling, M., Hansmann, M., Ott, G., Rosenwald, A., Gascoyne, R. D., Weinstock, D. M., Hiddemann, W., Klapper, W., & Weigert, O. (2018).Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles. Blood. 2018 Augusst 10. pii: blood-2018-03-837252. 

Chimeric Antigen Receptor T Cells are Active Against B and T Cell Lymphoma

Scarfò, I., Ormhøj, M., Frigault, M. J., Castano, A. P., Lorrey, S., Bouffard, A. A., van Scoyk, A., Rodig, S. J., Shay, A. J., Aster, J. C., Preffer, F. I., Weinstock, DM, & Maus, M. V. (2018). Anti-CD37 chimeric antigen receptor T cells are active against B and T cell lymphomas. Blood. 2018. 2018 August 14. pii: blood-2018- 04-842708. 

Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B Cell Lymphoma, Leg Type.

Zhou XA, Louissaint A Jr, Wenzel A, Yang J, Martinez-Escala ME, Moy AP, Morgan EA, Paxton CN, Hong B, Andersen EF, Guitart J, Behdad A, Cerroni L, Weinstock DM, Choi J. J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31988-2

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Nat Commun. 2018 May 22;9(1):2024

RhoA G17V is sufficient to induce autoimmunity and promotes T cell lymphomagenesis in mice.

Ng SY, Brown L, Stevenson K, deSouza T, Aster JC, Louissaint A, Weinstock DM. Blood. 2018 May 16. pii: blood-2017-11-818617

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R. Br J Haematol. 2018 Apr 19

Targeting minimal residual disease: a path to cure?

Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Nat Rev Cancer. 2018 Apr;18(4):255-263

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. 2018 Apr 5;173(2):470-484

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM^, Weinstock DM^. Activity of the PI3K-δ,γ inhibitor Duvelisib in a phase I trial and preclinical models of T-cell lymphoma.  Blood 2018;131:855-863. ^equal contribution

An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, Rettig MP, Wang B, Eissenberg LG, Ghobadi A, Gehrs LN, Prior JL, Achilefu S, Miller CA, Fronick CC, O'Neal J, Gao F, Weinstock DM, Gutierrez A, Fulton RS, DiPersio JF. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia

Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. (2018). Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia. Oncotarget, 9(8), 8027–8041.

Clinicogenetic risk modeling in ATL.

Yoshida, N., & Weinstock, D. M. (2018). Clinicogenetic risk modeling in ATL. Blood, 131(2), 159-160

 

 

See all our 2017 publications here.